An observational study in Coronary Artery Disease, sponsored by Seoul National University Hospital. Status unknown at 2 sites in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-11-22.
Sponsored by Seoul National University Hospital · Observational
The investigator will evaluate the clinical outcomes of the patients in whom the treatment strategy for their coronary stenosis were determined by fractional flow reserve measurement.
Inclusion criteria
Clinical outcomes
5,596 studies on the registry are indexed under Coronary Artery Disease; 955 are open to participants now.
This study's planned enrollment of 1,500 is above the median of 336 across 1,946 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with intermediate coronary stenosis by visual estimation
Exclusion Criteria:
Patients with intermediate coronary stenosis Patients with successful fractional flow measurement Feasible \> 9months clinical follow-up
Long-term MACE
Cardiac death, MI, target vessel revascularization, target lesion revascularization
Time frame: 5 years
Short-term MACE
Cardiac death, MI, TLR/TVR
Time frame: 9 months
This study is status unknown, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Seoul National University Hospital